Guardant Health (NASDAQ:GH) Director Sells $11,769.36 in Stock

by · The Markets Daily

Guardant Health, Inc. (NASDAQ:GH – Get Free Report) Director Musa Tariq sold 116 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $101.46, for a total transaction of $11,769.36. Following the transaction, the director directly owned 7,993 shares in the company, valued at approximately $810,969.78. This represents a 1.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Musa Tariq also recently made the following trade(s):

  • On Wednesday, November 19th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $96.25, for a total transaction of $11,165.00.
  • On Friday, October 17th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $66.95, for a total value of $7,766.20.

Guardant Health Trading Down 0.4%

GH stock traded down $0.37 during trading on Thursday, reaching $97.10. 3,021,881 shares of the stock were exchanged, compared to its average volume of 2,455,208. The firm’s 50 day moving average is $90.87 and its 200 day moving average is $66.79. The firm has a market cap of $12.24 billion, a P/E ratio of -30.25 and a beta of 1.58. Guardant Health, Inc. has a twelve month low of $29.91 and a twelve month high of $112.43.

Guardant Health (NASDAQ:GH – Get Free Report) last released its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.09. During the same period in the prior year, the company posted ($0.88) EPS. Guardant Health’s revenue was up 38.5% compared to the same quarter last year. As a group, analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Guardant Health

Hedge funds have recently modified their holdings of the business. Allworth Financial LP lifted its stake in shares of Guardant Health by 19.5% during the 3rd quarter. Allworth Financial LP now owns 844 shares of the company’s stock valued at $53,000 after buying an additional 138 shares in the last quarter. Swiss Life Asset Management Ltd purchased a new position in shares of Guardant Health in the third quarter valued at about $327,000. CIBC Bancorp USA Inc. bought a new position in shares of Guardant Health in the third quarter worth about $796,000. Danske Bank A S bought a new position in shares of Guardant Health in the third quarter worth about $62,000. Finally, Castleark Management LLC grew its position in shares of Guardant Health by 31.7% during the third quarter. Castleark Management LLC now owns 160,073 shares of the company’s stock worth $10,001,000 after purchasing an additional 38,513 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on GH shares. William Blair restated an “outperform” rating on shares of Guardant Health in a report on Thursday, September 25th. Guggenheim upped their target price on shares of Guardant Health from $56.00 to $67.00 and gave the stock a “buy” rating in a report on Thursday, September 25th. Evercore ISI raised their price target on shares of Guardant Health from $68.00 to $90.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Mizuho boosted their price objective on Guardant Health from $100.00 to $120.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Piper Sandler raised their target price on Guardant Health from $60.00 to $90.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Twenty-three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $95.52.

View Our Latest Research Report on GH

Guardant Health Company Profile

(Get Free Report)

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

Recommended Stories